Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.54 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017833 | 0.82 | CA1 (0.59) | CA12CA1CA9PREPRAB9A | |
| SCHEMBL12581975 | 0.81 | CA12 (0.55) | CA12CA1CA9PREPRAB9A | |
| SCHEMBL2221888 | 0.81 | CA12 (0.55) | CA12CA1CA9PREPRAB9A | |
| SCHEMBL2522567 | 0.80 | CA12 (0.54) | CA12CA1CA9PREPCYP1A2 | |
| SCHEMBL1118830 | 0.80 | PREP (0.50) | CA12CA1CA9PREPAPP | |
| SCHEMBL704912 | 0.77 | CA12 (0.58) | CA12CA1CA9PREPRAB9A | |
| SCHEMBL30186537 | 0.77 | CA12 (0.58) | CA12CA1CA9PREPRAB9A | |
| SCHEMBL3571948 | 0.77 | CA12 (0.44) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL30628285 | 0.77 | CA12 (0.44) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL1882570 | 0.77 | CA12 (0.61) | CA12CA1CA9PREPRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-11-08 | — | — | US | disclosed |
| EP-2516385-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. du Pont de Nemours and Company (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012087372-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011087837-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | CBR3, CBR1, Q6ZSR9 | CA12 1737/4885CA1 1469/4885CA9 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.